Niti Goel

Dr. Niti Goel

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
RFR Fleischmann
R Fleischmann
JVJ Vencovsky
J Vencovsky
RVR F van Vollenhoven
R F van Vollenhoven
DBD Borenstein
D Borenstein
JBJ Box
J Box
VSV Strand
V Strand
Tumour necrosis factor alpha (TNFalpha) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid arthritis (RA). Treatment with TNFalpha inhibitors reduces disease activity and improves outcomes for patients with RA. This study evaluated the efficacy and safety of certolizumab pegol 400 mg, a novel, poly-(ethylene glycol) (PEG)ylated, Fc-free TNFalpha inhibitor, as monotherapy in patients with active RA. In this 24-week, multicentre, randomised, double-blind, placebo-controlled study, 220 patients previously failing > or =1 disease-modifying antirheumatic drug (DMARD) were randomised 1:1 to receive subcutaneous certolizumab pegol 400 mg (n = 111) or placebo (n = 109) every 4 weeks. The primary endpoint was 20% improvement according to the American College of Rheumatology criteria (ACR20) at week 24. Secondary endpoints included ACR50/70 response, ACR component scores, 28-joint Disease Activity Score Erythrocyte Sedimentation Rate 3 (DAS28(ESR)3), patient-reported outcomes (including physical function, health-related quality of life (HRQoL), pain and fatigue) and safety. At week 24, the ACR20 response rates were 45.5% for certolizumab pegol 400 mg every 4 weeks vs 9.3% for placebo (p or =1 DMARD compared with placebo, and demonstrated an acceptable safety profile. NCT00548834.

1 April 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
AOAna-Maria Orbai
Ana-Maria Orbai
MWMaarten de Wit
Maarten de Wit
PMPhilip Mease
Philip Mease
JSJudy A Shea
Judy A Shea
LGLaure Gossec
Laure Gossec
AOAlexis Ogdie
Alexis Ogdie
Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA) clinical trials that represent both patients' and physicians' priorities. Methods We conducted (1) a systematic literature review (SLR) of domains assessed in PsA; (2) international focus groups to identify domains important to people with PsA; (3) two international surveys with patients and physicians to prioritise domains; (4) an international face-to-face meeting with patients and physicians using the nominal group technique method to agree on the most important domains; and (5) presentation and votes at the Outcome Measures in Rheumatology (OMERACT) conference in May 2016. All phases were performed in collaboration with patient research partners. Results We identified 39 unique domains through the SLR (24 domains) and international focus groups (34 domains). 50 patients and 75 physicians rated domain importance. During the March 2016 consensus meeting, 12 patients and 12 physicians agreed on 10 candidate domains. Then, 49 patients and 71 physicians rated these domains' importance. Five were important to >70% of both groups: musculoskeletal disease activity, skin disease activity, structural damage, pain and physical function. Fatigue and participation were important to >70% of patients. Patient global and systemic inflammation were important to >70% of physicians. The updated PsA core domain set endorsed by 90% of OMERACT 2016 participants includes musculoskeletal disease activity, skin disease activity, pain, patient global, physical function, health-related quality of life, fatigue and systemic inflammation. Conclusions The updated PsA core domain set incorporates patients' and physicians' priorities and evolving PsA research. Next steps include identifying outcome measures that adequately assess these domains.

1 March 2010 in mAbs
Verified
Journal Article
Closed access
PDF file
NGNiti Goel
Niti Goel
SSSue Stephens
Sue Stephens
Certolizumab pegol (Cimzia®) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab′) of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.

1 July 1998 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JRJeffrey Roseman
Jeffrey Roseman
ABAlfred A. Bartolucci
Alfred A. Bartolucci
AFAlan W. Friedman
Alan W. Friedman
JMJoann M. Moulds
Joann M. Moulds
NGNiti Goel
Niti Goel
GAGraciela S. Alarcón
Graciela S. Alarcón
Objective To determine the factors associated with disease activity in patients with recent‐onset (≤5 years) systemic lupus erythematosus (SLE) who were of Hispanic, African‐American, or Caucasian ethnicity. Methods Incident and prevalent cases of SLE, as defined by the American College of Rheumatology criteria for SLE, among the 3 ethnic groups were identified in Alabama (The University of Alabama at Birmingham) and Texas (The University of Texas‐Houston Health Science Center and The University of Texas Medical Branch at Galveston). Variables from the sociodemographic, clinical, immunologic, immunogenetic, behavioral, and psychological domains were obtained using validated instruments. Disease activity was ascertained with the Systemic Lupus Activity Measure (SLAM). Stepwise domain regressions with SLAM score as the dependent variable were performed. Final ethnic‐specific and overall regression models were obtained by entering variables that were retained in the domain regressions. Results SLAM scores at study entry were higher in the African Americans (mean ± SD 12.6 ± 6.9) and Hispanics (11.0 ± 6.2) than in the Caucasians (8.5 ± 3.7) (P ≤ 0.001). The final overall regression model (R2 = 28%) for higher SLAM score included the following variables: African‐American ethnicity, lack of private health insurance, abrupt disease onset, presence of anti‐Ro antibodies, absence of HLA‐DRB1*0301, higher levels of helplessness, and abnormal illness‐related behaviors. Conclusion Socioeconomic, immunologic, immunogenetic, behavioral, and psychological variables were all predictive of disease activity early in the course of SLE, irrespective of ethnic group. However, there remain ethnic group differences in disease activity that were not explained by these factors.

28 February 2007 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
TMTerry A. Mcnearney
Terry A. Mcnearney
JRJohn D. Reveille
John D. Reveille
MFMichael Fischbach
Michael Fischbach
AFAlan W. Friedman
Alan W. Friedman
JLJeffrey R. Lisse
Jeffrey R. Lisse
MMMaureen D. Mayes
Maureen D. Mayes
Objective: To determine the relative contributions of genetic, clinical, serologic, sociodemographic, and behavioral/psychological variables to early pulmonary involvement in the Genetics versus Environment in Scleroderma Outcome Study cohort.Methods: At the baseline visit (V0), 203 patients with systemic sclerosis (SSc) were examined (104 whites, 39 African Americans, and 60 Hispanics). We obtained sociodemographic, behavioral/psychological (illness behavior, social support, learned helplessness, smoking, drinking), clinical, serologic (autoantibodies), and genetic (HLA class II and FBN1 genotypes) factors; pulmonary function test results; electrocardiograms; and chest radiographs. Data analysis included Fisher's exact test, chi‐square test, Student's t‐test, analysis of variance, and stepwise linear and logistic regression methods.Results: Significant pulmonary involvement was seen in 25% of patients within 2.8 years of SSc diagnosis. At V0, pulmonary fibrosis was significantly higher in African Americans compared with whites or Hispanics. African Americans had significantly lower percent predicted forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) compared with whites and significantly lower percent predicted diffusing capacity for carbon monoxide (DLCO) compared with whites and Hispanics. Significant, independent associations impacting early pulmonary involvement included African American ethnicity, skin score, serum creatinine and creatine phosphokinase values, hypothyroidism, and cardiac involvement. Anticentromere antibody seropositivity was a significant, independent, protective factor for restrictive lung disease and FVC or DLCO values. African Americans had significantly increased frequencies of anti–topoisomerase I, fibrillarin, and RNP autoantibodies compared with whites. African Americans scored significantly lower on the Interpersonal Support Evaluation List and significantly higher on the Illness Behavior Questionnaire.Conclusion: Early pulmonary involvement in SSc appears to be influenced by several factors delineated by ethnicity, including racial, socioeconomic, behavioral, and serologic determinants.

1 February 2017 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
AOAna-Maria Orbai
Ana-Maria Orbai
MWMaarten de Wit
Maarten de Wit
PMPhilip J. Mease
Philip J. Mease
KDKristina C Duffin
Kristina C Duffin
MEMusaab Elmamoun
Musaab Elmamoun
AOAlexis Ogdie
Alexis Ogdie
Objective.: To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS).Methods.: At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants.Results.: We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient’s global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda.Conclusion.: The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.